在1型糖尿病孕妇队列中标准治疗基础上加用间断扫描式持续葡萄糖监测:对血糖控制和妊娠结局的影响
这项西班牙多中心观察性队列研究纳入300例1型糖尿病孕妇,168例仅用自我血糖监测(SMBG),132例在标准治疗基础上加用间断扫描式持续葡萄糖监测(isCGM)。isCGM组孕中期HbA1c中位数低于SMBG组(41.0 vs 43.2 mmol/mol,p=0.034),但孕中期至孕晚期HbA1c上升幅度更大(中位差值2.2 vs 1.1 mmol/mol,p=0.033);isCGM组新生儿低血糖风险更高(27.4% vs 19.1%;校正OR 2.20 [95%CI 1.14, 4.30]),大于胎龄儿、剖宫产和早产无差异。
要点
- isCGM组孕中期HbA1c中位数低于SMBG组(41.0 vs 43.2 mmol/mol,p=0.034),但孕中期至孕晚期HbA1c上升幅度更大(中位差值2.2 vs 1.1 mmol/mol,p=0.033)。
- isCGM组新生儿低血糖发生率高于非传感器使用者(27.4% vs 19.1%;校正OR 2.20 [95%CI 1.14, 4.30])。
- 大于胎龄儿、剖宫产和早产在两组间无差异(校正OR分别为0.73、1.33、1.05,95%CI均跨1)。
核心结论
- isCGM使用带来了初始的血糖控制改善,但未能持续。
- isCGM使用者的子代更可能出现新生儿低血糖,而巨大儿和早产率与接受标准治疗的孕妇相似。
研究设计与样本
- 西班牙多中心观察性队列研究,纳入300例1型糖尿病孕妇,其中168例使用SMBG(标准治疗),132例在标准治疗基础上加用isCGM。
- 除HbA1c外,在isCGM使用者中还评估了妊娠目标血糖范围(3.5-7.8 mmol/l)内的TIR、TBR和TAR。
- 采用逻辑回归模型分析不良妊娠结局,校正基线母体特征和中心。
主要发现
- isCGM组孕中期HbA1c中位数低于SMBG组(41.0 [IQR 35.5-46.4] vs 43.2 [IQR 37.7-47.5] mmol/mol,5.9% [IQR 5.4-6.4%] vs 6.1% [IQR 5.6-6.5%];p=0.034),其他孕期两组无差异(孕早期SMBG vs isCGM:47.5 [IQR 42.1-54.1] vs 45.9 [IQR 39.9-51.9] mmol/mol,6.5% [IQR 6.0-7.1%] vs 6.4% [IQR 5.8-6.9%];孕晚期43.2 [IQR 39.9-47.5] vs 43.2 [IQR 39.9-47.5] mmol/mol,6.1% [IQR 5.8-6.5%] vs 6.1% [IQR 5.7-6.5%])。
- 全队列HbA1c从孕中期至孕晚期轻度升高,isCGM组上升幅度显著高于SMBG组(中位差值2.2 vs 1.1 mmol/mol [0.2% vs 0.1%];p=0.033)。
- isCGM组新生儿低血糖发生率高于非传感器使用者(27.4% vs 19.1%;校正OR 2.20 [95%CI 1.14, 4.30])。
- 大于胎龄儿(40.6% vs 45.1%;校正OR 0.73 [95%CI 0.42, 1.25])、剖宫产(57.6% vs 48.8%;校正OR 1.33 [95%CI 0.78, 2.27])和早产(27.3% vs 24.8%;校正OR 1.05 [95%CI 0.55, 1.99])在两组间无差异。
- 排除大于胎龄儿或早产的敏感性分析同样显示isCGM使用与更高的新生儿低血糖风险相关(非大于胎龄儿:校正OR 2.63 [95%CI 1.01, 6.91];非早产:校正OR 2.52 [95%CI 1.12, 5.67])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this study was to assess whether the addition of intermittently scanned continuous glucose monitoring (isCGM) to standard care (self-monitoring of blood glucose [SMBG] alone) improves glycaemic control and pregnancy outcomes in women with type 1 diabetes and multiple daily injections. METHODS: This was a multicentre observational cohort study of 300 pregnant women with type 1 diabetes in Spain, including 168 women using SMBG (standard care) and 132 women using isCGM in addition to standard care. In addition to HbA1c, the time in range (TIR), time below range (TBR) and time above range (TAR) with regard to the pregnancy glucose target range (3.5-7.8 mmol/l) were also evaluated in women using isCGM. Logistic regression models were performed for adverse pregnancy outcomes adjusted for baseline maternal characteristics and centre. RESULTS: The isCGM group had a lower median HbA1c in the second trimester than the SMBG group (41.0 [IQR 35.5-46.4] vs 43.2 [IQR 37.7-47.5] mmol/mol, 5.9% [IQR 5.4-6.4%] vs 6.1% [IQR 5.6-6.5%]; p=0.034), with no differences between the groups in the other trimesters (SMBG vs isCGM: first trimester 47.5 [IQR 42.1-54.1] vs 45.9 [IQR 39.9-51.9] mmol/mol, 6.5% [IQR 6.0-7.1%] vs 6.4% [IQR 5.8-6.9%]; third trimester 43.2 [IQR 39.9-47.5] vs 43.2 [IQR 39.9-47.5] mmol/mol, 6.1% [IQR 5.8-6.5%] vs 6.1% [IQR 5.7-6.5%]). The whole cohort showed a slight increase in HbA1c from the second to the third trimester, with a significantly higher rise in the isCGM group than in the SMBG group (median difference 2.2 vs 1.1 mmol/mol [0.2% vs 0.1%]; p=0.033). Regarding neonatal outcomes, newborns of women using isCGM were more likely to have neonatal hypoglycaemia than newborns of non-sensor users (27.4% vs 19.1%; ORadjusted 2.20 [95% CI 1.14, 4.30]), whereas there were no differences between the groups in large-for-gestational-age (LGA) infants (40.6% vs 45.1%; ORadjusted 0.73 [95% CI 0.42, 1.25]), Caesarean section (57.6% vs 48.8%; ORadjusted 1.33 [95% CI 0.78, 2.27]) or prematurity (27.3% vs 24.8%; ORadjusted 1.05 [95% CI 0.55, 1.99]) in the adjusted models. A sensitivity analysis in pregnancies without LGA infants or prematurity also showed that the use of isCGM was associated with a higher risk of neonatal hypoglycaemia (non-LGA: ORadjusted 2.63 [95% CI 1.01, 6.91]; non-prematurity: ORadjusted 2.52 [95% CI 1.12, 5.67]). For isCGM users, the risk of delivering an LGA infant was associated with TIR, TAR and TBR in the second trimester in the logistic regression analysis. CONCLUSIONS/INTERPRETATION: isCGM use provided an initial improvement in glycaemic control that was not sustained. Furthermore, offspring of isCGM users were more likely to have neonatal hypoglycaemia, with similar rates of macrosomia and prematurity to those of women receiving standard care.
引用
- Perea V, Picón MJ, Megia A, et al. Addition of intermittently scanned continuous glucose monitoring to standard care in a cohort of pregnant women with type 1 diabetes: effect on glycaemic control and pregnancy outcomes. Diabetologia. 2022. PMID: 35546211. doi:10.1007/s00125-022-05717-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。